Pacritinib trial for Myelodysplastic Syndromes in adults and children initiated by NCI
A clinical trial is underway to evaluate pacritinib in patients aged 12 and older with Myelodysplastic Syndromes (MDS) and MDS/MPN.
Asset / Drug
Drug and asset intelligence for Pacritinib with 4 indexed intelligence signals across regulatory, clinical, competitive, and market developments.
No catalysts indexed for this entity yet.
July 7, 2026 · N/A
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.